Cargando…
Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study
BACKGROUND: The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non‐small cell lung cancer (NSCLC), compared to the same regimens admin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058314/ https://www.ncbi.nlm.nih.gov/pubmed/35434866 http://dx.doi.org/10.1111/1759-7714.14403 |
_version_ | 1784698086650544128 |
---|---|
author | Heraudet, Luc Delon, Tara Veillon, Rémi Vergnenègre, Charlotte Lepetit, Hélène Daste, Amaury Ravaud, Alain Zysman, Maéva Domblides, Charlotte |
author_facet | Heraudet, Luc Delon, Tara Veillon, Rémi Vergnenègre, Charlotte Lepetit, Hélène Daste, Amaury Ravaud, Alain Zysman, Maéva Domblides, Charlotte |
author_sort | Heraudet, Luc |
collection | PubMed |
description | BACKGROUND: The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non‐small cell lung cancer (NSCLC), compared to the same regimens administered without previous ICIs. METHODS: We retrospectively included all patients treated between 2015 and 2019 for an advanced NSCLC, receiving a salvage chemotherapy just after ICI (CAI group) comparing them to ICI naive patients (CWPI group) undergoing the same chemotherapy at Bordeaux University Hospital. The primary outcome was the time to treatment discontinuation (TTD), and secondary endpoints were overall survival (OS) and overall response rate (ORR). RESULTS: A total of 152 patients were included, with 34/23 (CAI/CWPI) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 27/12 gemcitabine (G) and 6/15 pemetrexed (PE). Characteristics were comparable, except for CAI treated with PB (more patients with an ECOG PS ≤1 [p <0.001]). Median number of lines received was higher in CAI for all groups. There was no difference between CAI and CWPI for TTD, OS and ORR. However, PB was associated with a nonsignificant increase in OS in the CAI group (HR = 0.65; 95% CI: 0.38–1.2, p = 0.17]. CONCLUSION: Our data showed no difference in TTD, OS and ORR regardless of chemotherapy, but a trend towards an increased OS with PB when given after an ICI, while patients received chemotherapy later in the CAI group. This suggests that a sequential combination of ICI followed by chemotherapy could be an interesting strategy in advanced NSCLC for selected patients. |
format | Online Article Text |
id | pubmed-9058314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-90583142022-05-03 Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study Heraudet, Luc Delon, Tara Veillon, Rémi Vergnenègre, Charlotte Lepetit, Hélène Daste, Amaury Ravaud, Alain Zysman, Maéva Domblides, Charlotte Thorac Cancer Original Articles BACKGROUND: The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non‐small cell lung cancer (NSCLC), compared to the same regimens administered without previous ICIs. METHODS: We retrospectively included all patients treated between 2015 and 2019 for an advanced NSCLC, receiving a salvage chemotherapy just after ICI (CAI group) comparing them to ICI naive patients (CWPI group) undergoing the same chemotherapy at Bordeaux University Hospital. The primary outcome was the time to treatment discontinuation (TTD), and secondary endpoints were overall survival (OS) and overall response rate (ORR). RESULTS: A total of 152 patients were included, with 34/23 (CAI/CWPI) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 27/12 gemcitabine (G) and 6/15 pemetrexed (PE). Characteristics were comparable, except for CAI treated with PB (more patients with an ECOG PS ≤1 [p <0.001]). Median number of lines received was higher in CAI for all groups. There was no difference between CAI and CWPI for TTD, OS and ORR. However, PB was associated with a nonsignificant increase in OS in the CAI group (HR = 0.65; 95% CI: 0.38–1.2, p = 0.17]. CONCLUSION: Our data showed no difference in TTD, OS and ORR regardless of chemotherapy, but a trend towards an increased OS with PB when given after an ICI, while patients received chemotherapy later in the CAI group. This suggests that a sequential combination of ICI followed by chemotherapy could be an interesting strategy in advanced NSCLC for selected patients. John Wiley & Sons Australia, Ltd 2022-04-17 2022-05 /pmc/articles/PMC9058314/ /pubmed/35434866 http://dx.doi.org/10.1111/1759-7714.14403 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Heraudet, Luc Delon, Tara Veillon, Rémi Vergnenègre, Charlotte Lepetit, Hélène Daste, Amaury Ravaud, Alain Zysman, Maéva Domblides, Charlotte Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study |
title | Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study |
title_full | Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study |
title_fullStr | Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study |
title_full_unstemmed | Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study |
title_short | Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study |
title_sort | effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: a retrospective study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058314/ https://www.ncbi.nlm.nih.gov/pubmed/35434866 http://dx.doi.org/10.1111/1759-7714.14403 |
work_keys_str_mv | AT heraudetluc effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT delontara effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT veillonremi effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT vergnenegrecharlotte effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT lepetithelene effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT dasteamaury effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT ravaudalain effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT zysmanmaeva effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy AT domblidescharlotte effectofpriorimmunotherapyontheefficacyofchemotherapyinadvancednonsmallcelllungcanceraretrospectivestudy |